Clinical Pipeline
MetaVia is in clinical development for two promising cardiometabolic diseases assets. The company is currently conducting a two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Each of the two-parts of the trial are designed to be 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical studies to evaluate the efficacy and safety of DA-1241. Part 1 is exploring the efficacy of DA-1241 versus placebo, and Part 2, is exploring the efficacy of DA-1241 in combination with sitagliptin (JANUVIA®), a DPP-4 inhibitor, versus placebo..
MetaVia is also conducting a two-part, Phase 1 randomized, placebo-controlled, double-blind study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of DA-1726 in obese, otherwise healthy subjects.